Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors are encouraged to join the class action, which allows for potential compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by April 6, 2026, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MREO